StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The termination of a $45M revenue stream from UnitedHealthcare could pressure MYGN's earnings. Similar coverage losses in other biotech cases led to significant stock price declines.
What happened, with direct paths to the underlying reporting
UnitedHealthcare ends coverage for MYGN GeneSight test effective H1 2025. Coverage loss may reduce revenue. 2024 GeneSight testing generated $45M, with commercial plans providing $40M and Medicaid $5M. This revenue loss poses a notable risk. Q4 adjusted EPS dropped to 3 cents and fourth-quarter sales slightly missed consensus. Earnings miss raises concerns. MYGN reaffirms 2025 EPS guidance and appoints a new CEO. Leadership change adds uncertainty to long‐term strategy.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.